CClinicalTrials.gg
Sign In
CompletedNCT01192919Updated Mar 2, 2020

Tumour Registry Lung Cancer (TLK)

An observational study in Lung Cancer, sponsored by iOMEDICO AG. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-02.

Sponsored by iOMEDICO AG · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,500
Ages
18 Years and older
Sex
All
01

Study summary

Overview of treatment reality in patients with bronchial carcinoma requiring systemic treatment and being treated by office-based oncologists in Germany.

Read the detailed description

The TLK is a prospective, longitudinal, nation wide cohort study that collects data on the treatment reality of patients with NSCLC and SCLC. At inclusion, data in patient characteristics, comorbidities, tumor characteristics, biomarker testing and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented. Patients are followed until death or for a maximum of 3 years.

02

Conditions studied

  • Lung Cancer

Browse trials for

Keywords

  • bronchial carcinoma
  • registry
  • real life treatment
  • cohort study
  • NSCLC
  • SCLC
  • Germany
03

In context

Lung Neoplasms

7,243 studies on the registry are indexed under Lung Neoplasms; 1,557 are open to participants now.

This study's enrollment of 2,500 is above the median of 189 across 1,514 observational studies indexed under Lung Neoplasms.

Browse Lung Neoplasms studies →

Lead sponsor

iOMEDICO AG is the lead sponsor of 52 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients with lung cancer requiring therapy

Inclusion criteria

  • histologically confirmed Small Cell Lung Cancer (SCLC), Non Small Lung Cancer (NSCLC) or neuroendocrine tumors receiving therapy
  • written informed consent
  • start of neoadjuvant, adjuvant or first-line therapy no longer than 4 weeks before informed consent

Exclusion criteria

Exclusion Criteria:

  • patients not receiving any systemic therapy
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,500 participants (actual)
Target follow-up
3 Years
Patient registry
Yes

Groups and cohorts

  • Patients with lung cancer

    Patients with lung cancer requiring therapy

06

What researchers measure

Primary outcomes

  1. Documentation of actually used therapy forms in bronchial carcinoma requiring treatment

    Time frame: 3 years per patient

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • von Verschuer U, Schnell R, Tessen HW, Eggert J, Binninger A, Spring L, Janicke M, Marschner N; TLK-Group (Tumour Registry Lung Cancer). Treatment, outcome and quality of life of 1239 patients with advanced non-small cell lung cancer - final results from the prospective German TLK cohort study. Lung Cancer. 2017 Oct;112:216-224. doi: 10.1016/j.lungcan.2017.07.031. Epub 2017 Sep 12. PubMed 28916198 ↗
  • Steffens CC, Elender C, Hutzschenreuter U, Dille S, Binninger A, Spring L, Janicke M, Marschner N; TLK-Group (Tumour Registry Lung Cancer). Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line - Results from the prospective German TLK cohort study. Lung Cancer. 2019 Apr;130:216-225. doi: 10.1016/j.lungcan.2019.02.026. Epub 2019 Feb 25. Erratum In: Lung Cancer. 2019 Sep;135:236. doi: 10.1016/j.lungcan.2019.07.013. PubMed 30885347 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 2, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01192919
Lead sponsor
iOMEDICO AG
Responsible party
Sponsor
First posted
Sep 1, 2010
Start date
Jan 2010
Primary completion
Jul 2016
Completion
Jul 2016
Last update
Mar 2, 2020

Study contacts

Hans-Werner Tessen, MD
principal investigator

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Lung Neoplasms→

Other studies from this sponsor

iOMEDICO AG

Start the discussion